Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vancocin Generics Launch As FDA Finds ViroPharma’s Label Fails “Significant New Use” Test

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA delivers an 87-page chef d'oeuvre that concludes the ViroPharma’s long-running battle to block ANDA approvals. In the citizen petition response, FDA rejects the firm’s scientific and legal arguments and concludes the antibiotic is not eligible for three years of Hatch-Waxman marketing exclusivity under a 2008 law. Although ViroPharma says it plans to sue FDA, the company may have bigger problems on its hands with an FTC investigation.

You may also be interested in...



FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions

46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.

FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions

46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.

Antibiotic Indications: Definition Of “Significant” Remains In FDA’s Hands After Vancocin Ruling

D.C. District Court Judge denies ViroPharma’s request for a preliminary injunction to require FDA to withdraw approval of three ANDAs, says company is unlikely to prevail in its suit challenging agency’s actions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel